Skip to content
Hers

Wegovy® Side Effects With Alcohol: What to Know

Can you drink on Wegovy®? Discover how alcohol can affect side effects, weight loss and blood sugar, and how to enjoy a drink more safely.

Reviewed by Claudia Berty, MBChB MRCGP DFSRH PGDipENT

Written by Editorial Team

Published Jan 13, 2026

Starting a new weight loss medication often brings up a long list of questions — one of the most common is about alcohol. Can you drink on Wegovy®?

The short answer: Yes, you can usually drink alcohol while on Wegovy® (semaglutide). But moderation matters.

There’s no rule that says you must avoid alcohol entirely. However, alcohol intake can worsen certain side effects of Wegovy®, slow down weight loss progress, and, in some cases, raise medical risks.

Let’s discuss how alcohol affects your body on semaglutide, potential Wegovy® side effects with alcohol, and how to drink safely (if you choose to) while staying on track with your weight management goals.

How Wegovy® Works

Wegovy® is a once-weekly injection containing semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist. It mimics GLP-1, a natural gut hormone.

By activating GLP-1 receptors, Wegovy®:

  • Slows down how quickly food moves through the stomach (gastric emptying)

  • Helps you feel fuller sooner and longer

  • Regulates blood glucose levels

When combined with a reduced-calorie diet and regular physical activity, Wegovy® can promote weight loss. Clinical trials show it’s an effective, safe weight loss treatment for many people.

In the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) approved Wegovy® for treating obesity in adults.

Other GLP-1 receptor agonists — like Ozempic® (also semaglutide, for type 2 diabetes), Saxenda® (liraglutide), and Mounjaro® (tirzepatide) — work in similar ways. As such, they have comparable side effects.

Wegovy® Side Effects With Alcohol

There’s no evidence that alcohol causes a direct drug interaction with semaglutide. But alcohol and GLP-1 medications share several overlapping side effects. Combining the two can make those effects more noticeable.

The most common side effects of Wegovy® include:

  • Nausea

  • Vomiting

  • Constipation

  • Diarrhoea

  • Abdominal pain

  • Heartburn or indigestion

  • A tired or weak feeling

  • Dizziness

Though these side effects are often mild and temporary, drinking might make them worse.

Why Alcohol Might Make Wegovy® Side Effects Worse

Alcohol itself can irritate the stomach lining, increase acid production, and slow digestion — similar to what semaglutide does.

When combining alcohol and Wegovy®, you may have:

  • More nausea or bloating after drinking

  • Heightened acid reflux or heartburn

  • Digestive upset, like constipation or diarrhoea

  • General upset stomach or discomfort

  • Headaches or fatigue

Certain alcoholic beverages tend to cause more trouble than others: For instance:

  • Wine can aggravate acid reflux for some.

  • Beer and fizzy drinks can trigger bloating or burping.

  • Sugary cocktails may spike blood sugar levels before dropping them later.

If you experience gastrointestinal (GI) symptoms from Wegovy®, adding alcohol can make them worse.

Alcohol and Weight Loss Progress

Technically, you can drink while using Wegovy®, but doing so can make weight loss harder or slower. Here’s why:

  • Empty calories. Alcohol provides calories without nutrients, which can slow your progress towards your weight loss goals.

  • Cravings and overeating. Alcohol lowers inhibitions, which can lead to overeating or reaching for late-night snacks.

  • Slower metabolism. Alcohol is processed by the liver before fat, which can delay fat burning.

  • Sleep and hormones. Drinking disrupts sleep and can affect hunger hormones, making weight gain more likely over time.

If your goal is sustainable weight loss and weight management, try to think of alcohol as an occasional indulgence rather than a regular habit.

Low Blood Sugar Risk (Hypoglycaemia)

While Wegovy® alone rarely causes low blood sugar (hypoglycaemia), the risk rises if you have type 2 diabetes or take other weight loss drugs or diabetes treatments like insulin or sulfonylureas.

Alcohol itself can lower blood glucose levels, especially when consumed on an empty stomach. This is because alcohol prevents the liver from releasing stored glucose.

Combined with semaglutide’s appetite-suppressing effects, this can increase the risk of hypoglycaemia.

Symptoms of low blood sugar may include:

  • Dizziness or lightheadedness

  • Shakiness or sweating

  • Hunger

  • Blurred vision

  • Fatigue

  • Fast heartbeat or palpitations

  • Slurred speech or confusion

If you experience these symptoms, have a quick source of sugar — like fruit juice, glucose tablets, or sweets — and let your general practitioner (GP) or private prescriber know.

Tip: Don’t skip meals before drinking, and limit the amount of alcohol you drink to stay safe.

Pancreatitis and Other Serious Risks

Inflammation of the pancreas (pancreatitis) is a rare but serious side effect of Wegovy®. Heavy or excessive alcohol consumption can increase that risk.

Alcohol is one of the most common causes of acute pancreatitis, second only to gallstones. Since GLP-1 medicines already carry a small pancreatitis risk, combining the two can heighten it further.

Seek medical attention immediately if you notice:

  • Persistent, severe abdominal pain

  • Feeling sick or vomiting

  • Fever

Your GP or a private healthcare professional may advise stopping the medication while the cause is assessed.

How Alcohol Affects Your Body on Semaglutide

When you’re on a GLP-1 like Wegovy®, several changes in how your body processes food and drink can alter your experience of alcohol.

Change

What Happens

Why It Matters

Reduced appetite

May drink on an empty stomach

Higher risk of low blood sugar

Slower digestion

Alcohol stays in system longer

May feel intoxicated faster

Lower body weight

Less fat + less body water

Stronger effects from same amount of alcohol

Altered metabolism

Liver enzymes process alcohol before fat

May slow fat loss + recovery

Even if you feel fine after one glass of wine or a pint, your tolerance may change significantly once you start taking Wegovy®.

5 Tips for Drinking Safely on Wegovy®

If you choose to drink, you can reduce potential risks with a few small adjustments.

1. Start Slowly

You may find alcohol affects you more strongly on Wegovy®. Begin with less than your usual amount of alcohol, and sip slowly to gauge tolerance.

2. Eat Before Drinking

Having food in your stomach helps regulate blood sugar levels and alcohol absorption. Opt for balanced snacks with complex carbohydrates, protein, and healthy fats — like wholemeal toast with nut butter or cheese and fruit.

3. Choose Lower-Calorie or Alcohol-Free Options

Swap sugary cocktails for lighter alcoholic drinks, such as a small glass of wine, a light beer, or spirits mixed with soda water and citrus. Alcohol-free and low-alcohol alternatives are also a great way to socialise without risking empty calories or discomfort.

4. Stay Hydrated

Both alcohol and semaglutide can cause dehydration. Drink plenty of water throughout the day and alternate alcoholic beverages with plain or sparkling water.

5. Check In With a Healthcare Professional

If you have any underlying health conditions — such as type 2 diabetes, high blood pressure (hypertension), or a history of pancreatitis — always speak with a healthcare professional before drinking. They can offer personalised medical advice and help you balance your weight loss goals with your lifestyle.

Can Wegovy® Reduce Alcohol Cravings?

Some early clinical trials and studies suggest that GLP-1 receptor agonists like semaglutide or liraglutide (Saxenda®) may reduce how much alcohol a person chooses to drink.

In one clinical trial, low doses of semaglutide reduced alcohol cravings in people with alcohol use disorder (AUD). Interestingly, it also lowered the number of cigarettes most participants smoked per day.

Another study included 227,866 people with alcohol use disorder. It found that semaglutide and liraglutide were associated with a decreased risk of hospitalisation due to AUD.

The mechanism isn’t fully understood, but researchers think GLP-1 may influence the brain’s reward system — the same area involved in cravings and addictive behaviours.

In short: Wegovy® isn’t a proven treatment for alcohol use disorder, but reduced cravings can be a welcome (and health-positive) side effect for some.

Wegovy® and Alcohol: In Summary

There’s no clear prohibition against alcohol while taking Wegovy®, but moderation is important. Here’s why:

  • Drinking may worsen the side effects of Wegovy®. For example, it can irritate your stomach, worsen nausea, and cause headaches.

  • In rare cases, it may worsen health risks. Excessive consumption of alcohol may raise your risk of pancreatitis and low blood pressure, for example.

  • Alcohol could slow weight loss. Generally, alcoholic drinks contain a lot of empty calories. This might sabotage your weight loss efforts.

If you decide to drink, start small, eat beforehand, stay hydrated, and be mindful of how your body reacts. When in doubt, ask your GP or private prescriber for tailored guidance.

Your weight loss journey is personal, and your healthcare team can help you find the balance that supports your goals safely.

20 Sources
  1. Bergmann NC, et al. (2022). Semaglutide for the treatment of overweight and obesity: a review. https://dom-pubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.14863

  2. Bode C, et al. (1997). Alcohol’s role in gastrointestinal tract disorders. https://pmc.ncbi.nlm.nih.gov/articles/PMC6826790/

  3. Chao AM, et al. (2019). Alcohol intake and weight loss during intensive lifestyle intervention for adults with overweight or obesity and diabetes. https://pmc.ncbi.nlm.nih.gov/articles/PMC6309276/

  4. Gorgojo-Martínez JJ, et al. (2022). Clinical recommendations to manage gastrointestinal adverse events in patients treated with GLP-1 receptor agonists: a multidisciplinary expert consensus. https://pmc.ncbi.nlm.nih.gov/articles/PMC9821052/

  5. Lähteenvuo M, et al. (2025). Repurposing semaglutide and liraglutide for alcohol use disorder. https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2825650

  6. Medicines and Healthcare products Regulatory Agency (MHRA). (2024). GLP-1 receptor agonists: reminder of the potential side effects and to be aware of the potential for misuse. http://www.gov.uk/drug-safety-update/glp-1-receptor-agonists-reminder-of-the-potential-side-effects-and-to-be-aware-of-the-potential-for-misuse

  7. Mederos MA, et al. Acute pancreatitis: a review. (2021). https://jamanetwork.com/journals/jama/article-abstract/2775452https://jamanetwork.com/journals/jama/article-abstract/2775452

  8. Medicines and Healthcare products Regulatory Agency (MHRA). (2024). MHRA approves GLP –1 receptor agonist semaglutide to reduce risk of serious heart problems in obese or overweight adults. https://www.gov.uk/government/news/mhra-approves-glp-1-receptor-agonist-semaglutide-to-reduce-risk-of-serious-heart-problems-in-obese-or-overweight-adults

  9. National Health Service (NHS). (2022). Acute pancreatitis. https://www.nhs.uk/conditions/acute-pancreatitis/

  10. National Health Service (NHS). (2022). Alcohol misuse. https://www.nhs.uk/conditions/alcohol-misuse/risks/

  11. National Health Service (NHS). (n.d.). Drink less alcohol. https://www.nhs.uk/better-health/drink-less/

  12. National Institute for Health Care and Excellence (NICE). (2023). Semaglutide for managing overweight and obesity. https://www.nice.org.UK/guidance/TA875/chapter/1-Recommendations

  13. Popoviciu M, et al. (2023). Emerging role of GLP-1 agonists in obesity: a comprehensive review of randomised controlled trials. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10341852/

  14. Public assessment report: National Procedures. Wegovy 0.25, 0.5, 1, 1.7, and https://mhraproducts4853.blob.core.windows.net/docs/067cffce55ebc124f4e3b9a14495a109cea5c599

  15. Smits MM, et al. (2021). Safety of semaglutide. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8294388/

  16. Wang CF, et al. (2025). Acute pancreatitis. https://www.ncbi.nlm.nih.gov/books/NBK482468/

  17. Wharton S, et al. (2021). Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. https://pmc.ncbi.nlm.nih.gov/articles/PMC9293236/

  18. Wegovy FlexTouch 0.25 mg, 0.5 mg, 1 mg, 1.7 mg and 2.4 mg solution for injection in pre-filled pen semaglutide. (2024). https://www.medicines.org.uk/emc/files/pil.13800.pdf

  19. Wilding JPH, et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183

  20. Wojtara M, et al. (2023). Glucagon-like peptide-1 receptor agonist for chronic weight management. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10533252/

Editorial Team

Related articles